Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 9 Results

Title
Intervention Indication Therapeutic Area Year Actions
Durvalumab with chemoradiation for untreated locally advanced unresectable oesophageal squamous cell carcinoma Chemoradiation , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Oesophageal cancer Head and Neck Cancer 2024 View  |  Download
Nivolumab (Opdivo) for Oesophageal Cancer Nivolumab (Opdivo; BMS-936558; ONO-4538) Oesophageal cancer Head and Neck Cancer 2017 View  |  Download
Nivolumab for oesophageal or gastro-oesophageal junction cancer - adjuvant Nivolumab (Opdivo; BMS-936558; ONO-4538) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2019 View  |  Download
Nivolumab in combination with cisplatin and fluorouracil for oesophageal cancer – first-line 5-Fluorouracil , Cisplatin (Platinol) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Oesophageal cancer Head and Neck Cancer 2019 View  |  Download
Nivolumab in combination with ipilimumab for oesophageal squamous cell carcinoma – first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Oesophageal cancer Head and Neck Cancer 2019 View  |  Download
Pembrolizumab (KEYTRUDA) for advanced, metastatic oesophageal cancer – second line Pembrolizumab (Keytruda; MK-3475) Gastro-oesophageal junction cancer , Oesophageal cancer Gastrointestinal Cancer , Head and Neck Cancer 2017 View  |  Download
Pembrolizumab in addition to cisplatin and fluorouracil for recurrent locally advanced or metastatic oesophageal cancer – First-line 5-Fluorouracil , Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475) Oesophageal cancer Head and Neck Cancer 2019 View  |  Download
Pembrolizumab with radiotherapy and chemotherapy for treating unresectable oesophageal cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) , Radiotherapy Oesophageal cancer Head and Neck Cancer 2023 View  |  Download
Tislelizumab for oesophageal cancer – second line Tislelizumab (BGB-A317; BGBA-317) Oesophageal cancer Head and Neck Cancer 2021 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications